U.S. flag An official website of the United States government
  1. Home
  2. Drugs
  3. News & Events for Human Drugs
  4. Drug Development Considerations for the Prevention of Healthcare-Associated Infections - 08/30/2022
  1. News & Events for Human Drugs

Workshop

Event Title
Drug Development Considerations for the Prevention of Healthcare-Associated Infections
August 30, 2022


Date:
August 30, 2022
Time:
8:30 AM - 5:00 PM ET

DESCRIPTION AND SUMMARY

The Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA) are co-sponsoring this public virtual workshop.

Discussions are planned around the following topics/areas:

  • The current state of development of pathogen-directed products used to prevent healthcare-associated infections
  • Evidence supporting decolonization and pathogen reduction (in colonized patients) as a strategy to prevent infection and transmission of antimicrobial-resistant healthcare-associated pathogens
  • Antimicrobial resistance threats as potential targets for decolonization and pathogen reduction
  • Challenges and potential approaches to drug development and registration of products for the prevention of healthcare-associated infections

REQUEST FOR ORAL PRESENTATIONS

During online registration, you may indicate if you wish to present during a public comment session or participate in a specific session, and which topic(s) you wish to address. We will do our best to accommodate requests to make public comments. Individuals and organizations with common interests are urged to consolidate or coordinate their presentations, and request time for a joint presentation, or submit requests for designated representatives to participate in the focused sessions. All requests to make oral presentations must be received by August 15, 2022, and must be emailed to Sunita Shukla (Sunita.Shukla@fda.hhs.gov) with the title and brief description of your topic.

We will determine the amount of time allotted to each presenter (no more than 5 minutes) and the approximate time each oral presentation is to begin. We will select and notify participants, if selected as presenters, by August 18, 2022. If selected for presentation, any presentation materials must be emailed to Sunita Shukla (Sunita.Shukla@fda.hhs.gov) no later than August 24, 2022. No commercial or promotional material will be permitted to be presented during the workshop.

MEETING MATERIALS

All meeting materials—including agenda, panelist affiliations/disclosures, speaker slides, workshop recording, and transcript—will be posted here shortly before and/or after the completion of the workshop. Please check this site regularly for updates.

ONLINE ATTENDANCE (WEBCAST)

This virtual public workshop will be webcast via Zoom. You will receive a link for viewing via email, or you can check back here for the link on the day of the event.

For more information about Zoom, please visit this Zoom Support Webpage.

EVENT POINT OF CONTACT

Lori Benner and/or Antoinette Ziolkowski
Center for Drug Evaluation and Research
Food and Drug Administration
10903 New Hampshire Ave.
Bldg. 22, Room 6221
Silver Spring, MD 20993-0002
301-796-1300

REGISTRATION

This meeting will be held in virtual format only. Registration is required for online attendance and will be available until 12 p.m. EDT on August 29, 2022. To register for this workshop visit here:

Back to Top